Article

Alcon completes acquisition of Sirion drugs

Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.

Huenenberg, Switzerland

-Alcon Laboratories Inc. has received regulatory approval and finalized the acquisition of the rights in the United States for difluprednate ophthalmic emulsion 0.05% emulsion (Durezol) and the global rights, excluding Latin America, for cyclosporine (Zyclorin) from Sirion Therapeutics Inc. Alcon immediately assumed responsibility for all marketing, promotion, and sales of the difluprednate formulation.

The difluprednate formulation is a topical ophthalmic corticosteroid used to treat postoperative inflammation and pain associated with ocular surgery. It received FDA approval in 2008. The cyclosporine formulation, not approved by the FDA, is a topical ophthalmic immunomodulator and immunosuppressive agent under clinical investigation to treat dry eye and other ocular surface diseases.

“This acquisition reinforces our ability to drive growth in the near-term with the acquisition of [difluprednate] and add products to our long-term research pipeline with [cyclosporine],” said Stuart Raetzman, Alcon’s vice president of global marketing and area president for the United States. “[Difluprednate’s] unique capability to . . . treat both inflammation and pain [effectively and quickly] following ocular surgery makes it a great fit for Alcon’s . . . product portfolio.”

In related news, Alcon management, in a news release, said that it is continuing to evaluate options to acquire Sirion’s ganciclovir ophthalmic gel 0.15% formulation (Zirgan), an antiviral recently approved by the FDA for the treatment of acute herpetic keratitis (corneal ulcers).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.